Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
2022
Xuanting Wang | Carolina Q. Sacramento | Steffen Jockusch | Otávio Augusto Chaves | Chuanjuan Tao | Natalia Fintelman-Rodrigues | Minchen Chien | Jairo R. Temerozo | Xiaoxu Li | Shiv Kumar | Wei Xie | Dinshaw J. Patel | Cindy Meyer | Aitor Garzia | Thomas Tuschl | Patrícia T. Bozza | James J. Russo | Thiago Moreno L. Souza | Jingyue Ju
In this paper, the hepatitis C virus inhibitors Pibrentasvir and Ombitasvir are found to inhibit the SARS-CoV-2 exonuclease and are shown to have therapeutic potential when combined with SARS-CoV-2 polymerase inhibitors in viral cell cultures.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals
